Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.31 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783169 | 0.98 | HTR2A (0.46) | HTR2AHTR2CHTR2BTAAR1CYP1A2 | |
| SCHEMBL16067266 | 0.87 | HTR2A (0.37) | HTR2AHTR2CHTR2BTAAR1CYP1A2 | |
| SCHEMBL10405923 | 0.76 | IMPDH2 (0.33) | IMPDH2IMPDH1 | |
| SCHEMBL1820953 | 0.76 | IMPDH2 (0.32) | IMPDH2IMPDH1 | |
| SCHEMBL8563125 | 0.76 | IMPDH2 (0.49) | IMPDH2IMPDH1 | |
| SCHEMBL8565835 | 0.74 | IMPDH1 (0.31) | IMPDH2IMPDH1 | |
| SCHEMBL29793173 | 0.74 | IMPDH2 (0.41) | HTR2BIMPDH2IMPDH1KDM4E | |
| SCHEMBL8564172 | 0.74 | IMPDH2 (0.41) | HTR2BIMPDH2IMPDH1KDM4E | |
| SCHEMBL15071874 | 0.74 | CA2 (0.42) | IMPDH2IMPDH1 | |
| SCHEMBL1784681 | 0.72 | IMPDH1 (0.40) | HTR2BIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262508-B1 | SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | BIOELECTRON TECH CORP (US) | 2018-10-03 | — | — | EP | disclosed |
| US-9090576-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8716527-B2 | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases | EDISON PHARMACEUTICALS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | PTC THERAPEUTICS, INC. | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124679-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | HTR2A 1828/4885HTR2C 3183/4885HTR2B 3414/4885 |
| US-20140329860-A1 | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES | NQO1, TXNRD2, MT-ND2 | HTR2A 1828/4885HTR2C 3183/4885HTR2B 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.